Glenmark Pharmaceuticals Limited
GLENMARK
Κατάταξη σε μετοχές
#2745
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Τιμή μετοχής
$24.28
Κεφαλαιοποίηση
$6.85B
Αλλαγή (1 ημέρα)
-0.46%
Αλλαγή (1 έτος)
15.18%
Χώρα
IN
Εμπόριο Glenmark Pharmaceuticals Limited (GLENMARK)
Κατηγορία
Healthcare
Έσοδα για την Glenmark Pharmaceuticals Limited (GLENMARK)
Έσοδα τον Jun 2026 TTM: $1.96B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Glenmark Pharmaceuticals Limited, τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $1.96B. Το 2024, η εταιρεία είχε έσοδα $1.52B αύξηση σε σχέση με τα έσοδα του έτους 2023, τα οποία ήταν $1.42B. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Glenmark Pharmaceuticals Limited από 2004 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $1.96B | 25.27% |
| 2025 | $1.56B | 3.03% |
| 2024 | $1.52B | 6.93% |
| 2023 | $1.42B | -12.51% |
| 2022 | $1.62B | 8.43% |
| 2021 | $1.49B | 5.68% |
| 2020 | $1.41B | -0.43% |
| 2019 | $1.42B | 1.94% |
| 2018 | $1.39B | -0.46% |
| 2017 | $1.40B | 22.48% |
| 2016 | $1.14B | 8.80% |
| 2015 | $1.05B | 5.93% |
| 2014 | $991.82M | 8.31% |
| 2013 | $915.73M | 15.49% |
| 2012 | $792.91M | 19.82% |
| 2011 | $661.74M | 18.85% |
| 2010 | $556.78M | 33.58% |
| 2009 | $416.81M | -16.99% |
| 2008 | $502.10M | 73.91% |
| 2007 | $288.72M | 69.74% |
| 2006 | $170.10M | 21.35% |
| 2005 | $140.17M | 59.84% |
| 2004 | $87.69M | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 237.78% |
IN
|
